within Pharmacolibrary.Drugs.ATC.A;

model A06AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A06AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Drugs classified under ATC code A06AX02 are typically oral agents that release carbon dioxide in the gastrointestinal tract to promote laxative effects, such as 'sodium bicarbonate combined products' and similar effervescent salts. They are used as osmotic or stimulant laxatives in constipation and bowel preparation. These drugs are not widely used today compared to other modern laxatives and have limited clinical application.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models or human pharmacokinetic parameterization found for orally administered carbon dioxide producing drugs in adults or children; parameters below are estimated based on common knowledge of salt solution oral absorption and rapid gastric CO2 release.</p><h4>References</h4><ol><li><p>Barillaro, V, et al., &amp; Piell, G (2005). Oral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing. <i>The AAPS journal</i> 7(1) E149–E155. DOI:<a href=&quot;https://doi.org/10.1208/aapsj070116&quot;>10.1208/aapsj070116</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16146337/&quot;>https://pubmed.ncbi.nlm.nih.gov/16146337</a></p></li><li><p>DeYoung, MB, et al., &amp; Herbert, P (2011). Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. <i>Diabetes technology &amp; therapeutics</i> 13(11) 1145–1154. DOI:<a href=&quot;https://doi.org/10.1089/dia.2011.0050&quot;>10.1089/dia.2011.0050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21751887/&quot;>https://pubmed.ncbi.nlm.nih.gov/21751887</a></p></li><li><p>Ozesme Taylan, G, et al., &amp; García-González, CA (2025). Core-shell aerogel design for enhanced oral insulin delivery. <i>International journal of pharmaceutics</i> 669 125038–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ijpharm.2024.125038&quot;>10.1016/j.ijpharm.2024.125038</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39645063/&quot;>https://pubmed.ncbi.nlm.nih.gov/39645063</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A06AX02;
